Abstract:e15078 Background: Immune checkpoint blockades (ICBs) have been approved for colorectal cancer (CRC) with microsatellite instability high (MSI-H). However, 50% to 60% MSI-H and almost 100% microsatellite stability (MSS) CRC patients can’t benefit from ICBs treatment. How to warm these “cold tumor” for boosting response to ICBs is still a problem. We aimed to integrate the expression signatures of T cell activation, exclusion and dysfunction to generate immune microenvironment subtypes which may guide precision immunotherapy. Methods: RNA-Seq of 596 CRC patients from The Cancer Genome Atlas were analyzed. T cell activation, dysfunction and exclusion signatures were calculated from TIDE model algorithm. Unsupervised clustering was used to classify CRC into various immune subtypes. Mann Whitney U test and Kruskal test were used to compare the difference among two or more than two groups. COX regression multivariate analysis was applied to analyze the association of subtypes with overall survival (OS). Results: Compared with 543 patients with MSS, 83 patients had significantly higher expression of T cell activation related genes (including CD8A, CXCL9, CXCL10, GZMB, IFNG et al) and immune checkpoint genes (including PD-L1, PD-1, LAG3 et al.), but lower signatures scores of M2-like tumor-associated macrophage (TAM) and T cell exclusion ( all P value<0.001). Based on expression signatures of myeloid-derived suppressor cell (MDSC), cancer-associated fibroblast (CAF), M2-like TAM, cytotoxic T-lymphocytes (CTL) and PD-L1, all the patients were clustered into four subtypes. Cluster 4 was enriched by MSI-H and characterized with high T cell activation and moderate T cell dysfunction and exclusion. Comparatively, another MSI-H enriched Cluster 1 had both high CTL and T cell dysfunction which indicated that activated T cell might be escaped by tumor cell. Cluster 2 and Cluster 3 were enriched by MSS and characterized with moderate T cell activation and high T cell exclusion. In survival analysis, Cluster 4 had prolonged OS (HR [95% CI]=0.46 [0.27-0.80]) compared with Cluster 1, 2 and 3, after adjusted for age, pathological stage, tumor residue, MSI status, BRAF and PIK3CA mutations. In MSS, Cluster 4 also had better prognosis than the other three clusters (HR [95% CI]=0.38 [0.20-0.73]). Conclusions: Our findings provide evidence to guide further patient stratification in ICBs treatment. The distinct immune subtypes of CRC also paved the way of combination immunotherapy based on immune microenviroment to turn “cold tumor” into “hot tumor”.

Classification of Estrogen Receptor-Positive Breast Cancer Based on Immunogenomic Profiling and Validation at Single-Cell Resolution

Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes

Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment

Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape

A Novel Immune Subtype Classification of ER-positive, PR-negative and HER2-negative Breast Cancer Based on the Genomic and Transcriptomic Landscape

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Identification Of Immune Microenvironment Subtypes Of Breast Cancer In Tcga Set: Implications For Immunotherapy.

Identification of Immune Subtypes to Guide Immunotherapy and Targeted Therapy in Clear Cell Renal Cell Carcinoma

A Breast Cancer Classification and Immune Landscape Analysis Based on Cancer Stem-Cell-related Risk Panel

Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients

Establishment of a Tumor Immune Microenvironment-Based Molecular Classification System of Breast Cancer for Immunotherapy

Identification of an immune classification for cervical cancer and integrative analysis of multiomics data

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (-) Breast Cancer

Development and Validation of Novel Microenvironment-Based Immune Molecular Subtypes of Breast Cancer: Implications for Immunotherapy.

Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling

A Single-Sample Mrna Molecular Classification of Bladder Cancer Predicting Prognosis and Response to Immunotherapy

Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment

Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC

Comprehensive Immune Transcriptomic Subtypes of Colorectal Cancer for Development of Precision Immunotherapy.

Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer

Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses